Aigner KR, Lavinski Y, Gailhofer S. Tumor response and the quality of life after isolated hypoxic pelvic perfusion for advanced G3 cervical cancer: A case series.
Int J Surg Case Rep 2021;
77:816-821. [PMID:
33395903 PMCID:
PMC7724000 DOI:
10.1016/j.ijscr.2020.11.050]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2020] [Accepted: 11/07/2020] [Indexed: 01/19/2023] Open
Abstract
Standard treatment of cervical cancer is associated with considerable toxicity and permanent adverse events.
Isolated hypoxic pelvic perfusion overcomes chemoresistance and generates effective and onlasting tumor response.
Complete and durable clinical and radiological remissions are achieved with no identifiable signs of systemic toxicity.
Quality of life is maintained.
Introduction
We present a case series of three patients with advanced cervical cancer who either refused the standard of care systemic or chemoradiation treatment or did not benefit from it.
Methods
We treated patients with isolated hypoxic pelvic perfusion (HPP).
Results
Two patients achieved complete clinicopathologic response and one patient required surgical excision of the necrotic residual mass containing no viable cancer cells. There were no long-term systemic or local side effects. All patients are cancer free for up to 15 years after conclusion of treatment.
Conclusion
HPP is an effective option for treatment of advanced cervical cancer that generates rapid and onlasting remissions at low side effects. Gynecologic oncologists shall be aware of HPP to facilitate wider adaption of our technique.
Collapse